CDK4 and breast carcinoma: In breast cancer, the addition of fulvestrant to alisertib failed to improve response rates or progression-free survival; however, alisertib monotherapy showed therapeutic potential in endocrine- and CDK4/6 inhibitor–resistant settings [29].